# A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

> **NCT00250432** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 204 (actual)

## Conditions studied

- Invasive Candidiasis

## Interventions

- **DRUG:** caspofungin acetate

## Key facts

- **NCT ID:** NCT00250432
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-01
- **Final completion:** 2008-03
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2017-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250432, "A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT00250432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*